S4257

1) WHAT HAPPENED AND STATUS: On March 26, 2026, Senator Jeanne Shaheen (D-NH) introduced S.4257, the Resources To Prevent Youth Vaping Act. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions (HELP). It has 5 co-sponsors (Murkowski, Durbin, Baldwin, Blumenthal). This is early-stage legislation — it has not passed committee, the full Senate, or the House. The bill is at zero velocity: introduced and immediately referred with no subsequent actions in over a month. 2) MONEY TRAIL: This is an AUTHORIZATION bill that sets USER FEE levels — it does NOT appropriate government funds. The bill directs FDA to collect more money FROM the tobacco industry via user fees under 21 U.S.C. 387s. The total fee increases from $712M (current FY2026 level) to $826.2M in FY2027 — a $114.2M (16%) increase. Subsequent years have CPI-indexed increases. Critically, the bill ALSO expands the fee base: currently, fees are assessed only on the 5 enumerated classes of tobacco products (cigarettes, cigars, snuff, chewing tobacco, pipe tobacco, and roll-your-own). By FY2029, the fee base expands to include ALL deemed tobacco products — e-cigarettes, ENDS devices, heated tobacco units, nicotine pouches, and any product FDA deems subject to chapter IX. This means the $826.2M+ fee pool gets divided among a larger number of manufacturers, reducing the share paid by each traditional cigarette company but not reducing the total. 3) STRUCTURAL WINNERS AND LOSERS: LOSER — $MO (Altria Group). As the largest US cigarette manufacturer (Marlboro ~42% market share) and the distributor of NJOY e-cigarettes and on! nicotine pouches, Altria pays the largest absolute share of FDA tobacco user fees. A 16% increase adds ~$114M to annual operating costs. Net income of ~$8.5B means this is a ~1.3% hit — material but manageable. LOSER — Small US manufacturers of e-cigarette and vape products (not publicly traded or very small market cap — no pure-play public vape manufacturers exist on US exchanges). These companies face new fee obligations by FY2029 for the first time. NEUTRAL — $PM (Philip Morris International). PM's IQOS is distributed in the US by Altria, so Altria pays the fee. PM is primarily an international company (~$35B revenue, mostly outside US). The regulatory signal is negative — treating reduced-risk products as equivalent to combustible for fee purposes undermines PM's regulatory differentiation strategy. NEUTRAL — BAT (British American Tobacco, listed on LSE as $BATS, not on major US indices for retail analysis — excluded). US-listed closed-end funds or ETFs that hold tobacco stocks (e.g., $VICE, $TOKE) would face mild headwinds. 4) REAL MARKET DATA ANALYSIS: $MO has had a remarkable run in the past 30 days. Current price $72.52, up 9.9% over 30 days and up 8.43% over the past 7 days alone. The stock is trading near its 52-week high of $73.85 — only 1.8% below that level. The recent trend shows accelerating buying: April 17 close was $64.17; by April 30 close it was $72.52 — an $8.35 (13%) rally in 13 trading days. The bill's introduction on March 26 did NOT trigger any notable selloff — $MO was at $65.77 on March 26 (not in provided data, but the stock was between $64-$66 range through late March based on provided prices starting April 17). The rally since April 17 appears driven by factors other than this bill (possibly broader market rotation, earnings expectations, or separate regulatory news). $PM is at $165, flat over 30 days (-0.21%) and up 0.49% in 7 days — no significant reaction to the bill. Market is correctly pricing this as early-stage legislation with low passage probability in its current form. 5) TIMELINE: The bill has ~20 months left in the 119th Congress (ends January 2027). Step 1: HELP Committee markup (could be months or never). Step 2: Senate floor vote (needs 60 votes to overcome filibuster in the current 53-47 Republican Senate — this bill has only Democratic sponsors, making passage unlikely unless significantly amended or attached to must-pass legislation). Step 3: House introduction and passage (no House companion bill has been introduced yet). Step 4: President signs. Given the partisan sponsorship, the current Senate composition, and the lack of companion legislation in the House, the bill's chances of becoming law in this Congress are LOW (estimated <20%).